Trial Profile
A phase I study of oral navelbine [vinorelbine] and capecitabine in the treatment of metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 28 Feb 2011 Planned end date changed from 1 Aug 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 10 Nov 2009 Planned end date changed from 1 Aug 2008 to 1 Apr 2010 as reported by ClinicalTrials.gov
- 29 Oct 2005 New trial record.